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Disclaimer
Objectives
• Discuss  pain in the larger context of suffering
• Identify the differences between nociceptive and 
neuropathic pain
• Review pharmacological treatment strategies for 
nociceptive and neuropathic pain
• Discuss management of rapidly escalating pain
Chronic non-cancer pain is a 
separate entity from EOL pain, with 
different management principles and 
challenges.   
Fast Facts and Concepts
www.capc.org
↓
“For Providers”
Care Settings
• Office
• Care Center/Nursing Home
• Hospital
• Hospice Room in Community Hospital
• Home
3 C’s of Symptom Management
•Comfortable
•Contented 
•Connected
Pain Management in Family Medicine
• Know the story
• Match pharmacology to individual need
• Titrate medication to response 
• Communicate effectively
• Understand OME
• Understand opiate incomplete cross-tolerance
• Be able to recognize and reverse opiate toxicity
• Be able to manage a pain crisis
Pain Definition
“…….a somatic perception containing: (1) a 
bodily sensation with qualities like those reported 
during tissue-damaging stimulation, (2) an 
experienced threat associated with this sensation, 
and (3) a feeling of unpleasantness or other 
negative emotion based on this experienced 
threat.“  
Price DD. Psychological Mechanisms of Pain and Analgesia In 
Progress in Pain Research and Management, IASP Press, Seattle 
1999. Vol 15
Total Pain
• Physical
• Emotional
• Social/relational
• Spiritual
• Bureaucratic
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“Death is not a strictly medical 
event, and many patients’ and 
families’ most pressing needs 
are not medical in nature.”
Panel comments, Dying in America: Improving Quality 
and Honoring Individual preferences Near the End of 
Life, Institute of Medicine. http://www.iom.edu/Reports.  
Released 9/14/14  
“The patient’s story is the 
container for meaning.”
Rachel Naomi Remen
End of Life
• No exact definition
• Multiple trajectories to death
• NIH
“People can, in some respects, be considered to be approaching 
death from the moment they are born.”
National Institutes of Health. National institutes of health state-of-the-science 
conference statement of improving end-of-life care, 
http://consensus.nih.gov/2004/2004EndOfLifeCareSOS024html.htm
• Practical working definition:  life-limiting illness with high 
likelihood for death within 6-12 months

Pain
• Location
• Quality
• Quantity
• Setting 
• Chronology
• Associated symptoms
• Aggravating and alleviating factors
Intensity
• Awareness 1-2
• Nuisance 3-4
• Aggravation 5-6
• Preoccupying (“All I think about”) 7-8
• Excruciating (“Worst ever”) 9-10
Wong-Baker Facial Pain Scale
No Pain Worst Pain Ever
Nociceptive Pain
A nociceptor is a nerve fiber preferentially sensitive to a 
noxious stimulus. 
Nociceptive pain is the perception of nociceptive input, 
usually due to tissue damage. 
Rosenquist E, Aronson M, Park L  Definition and pathogenesis of chronic 
pain.  UpToDate
Nociceptive Pain
• Somatic
• Arises from injury to body tissues
• Well localized but varies in description and experience
• Visceral
• Arises from viscera mediated by stretch receptors
• Poorly localized
• Deep, dull, cramping
Rosenquist E, Aronson M, Park L  Definition and pathogenesis of 
chronic pain.  UpToDate
Neuropathic Pain
• Pain caused by a primary nerve injury or dysfunction in 
the nervous system
• Responsible lesion may be of any type and occur at any 
location along the sensory transmission pathways
• May be directly related to a life-threatening disease or by 
a co-morbidity
• May be constant or fluctuating intensity
• May be paroxysmal 
• May be spontaneous or provoked by stimulus
• Descriptors may help identify pain as neuropathic
Oxford Textbook of Palliative Medicine, Fourth Edition.  Hanks, 
Cherry, Christakis, et al
Neuropathic Pain Descriptors
• Burning
• Sharp
• Stabbing
• Squeezing
• Shooting
• Pins and needles
• Electric shock
• Cold
Patients often have combination of 
neuropathic and nociceptive pain 
(“mixed pain”).  Effective pain 
management should address both 
types.  
Start Simple
• Acetaminophen (Scheduled)
• Caution 
• Liver disease 
• Pts on warfarin
• Avoid alcohol with significant scheduled doses
• Avoid single agent + combination analgesic products
• NSAIDS
• Caution:
• Renal disease
• Hypertension
• History of ulcers/GI bleeding
• CHF
• Advanced liver disease
• Concurrent anticoagulants  
Codeine
• Constipating
• Direct anti-tussive effect
• Metabolic Variation
• Converted to MORPHINE via CYP2D6 pathway
• Approximately 7% of Caucasians lack CYP2D6 activity
• Negligible analgesic effect in these patients
• “Ultra-rapid metabolizers” (small subset)
• Potential for extensive conversion to morphine and associated adverse 
effects
• Impact may be greatest in pediatric population
Tramadol
• Weak opioid mu-receptor agonist
• Inhibits uptake of serotonin and norepinephrine
• SNRIs have the same effect
• Fairly rapid pain relief
• Potential to ↓ seizure threshold
• Serotonin syndrome potential
• SNRI
• SSRI
• Start with 50 mg PO every 4 hours
• Maximum dose 400 mg/day
• Renal or hepatic impairment requires dose adjustment
Dworkin R, O’Connor A, Audette J, et al. Recommendations for the 
pharmacological management of neuropathic pain: an overview and 
literature update. Mayo Clinic Proc March 2010; 85(3)(suppl):S3-S14
Hydrocodone
• Hydrocodone + acetaminophen
• Vicodin
• Lortab
• In 2007, 99% of worldwide hydrocodone consumed in US
International Narcotics Control Board Report 2008
• Schedule III  Schedule II August 2014
• Converted via CYP2D6 pathway to HYDROMORPHONE
• Zohydro ER approved by FDA in 2014
• Concerns re: potential for substance abuse
• FDA review panel recommended 12-2 against approval
• 30 US states requested that it not be approved in capsule form
Rita Rubin
WebMD Health News
2/27/14
Opioid Equivalents
Drug Oral/Rectal (mg) IV/SC (mg)
Morphine 30 10
Oxycodone 20 N/A
Hydromorphone 7.5 1.5
Hydrocodone 30 N/A
Fentanyl N/A 100 mcg (single dose)
Opiate Adverse Reactions
• Constipation
• All patients on regular opiates must have a bowel regimen 
prescribed
• Docusate has no proven efficacy
• Stimulant (sennoside) excellent first  choice
• Sedation
• Pruritus
• Urinary Retention
• Nausea
• Neuro-excitability
• Myoclonus
• Allodynia
• Ordinarily non-painful stimuli evoke pain
Opiate Principles
• Respiratory depression risk highest in opioid-naïve pts
• Start low and titrate
• Prescribe smaller amounts of short-acting opiate initially
• See patients 1-2 times/wk to adjust dosages until pain is 
consistently in 2-3/10 range
• Avoid mixing opiates when possible
• Morphine SR BID + oxycodone Q 4 hours PRN
• One SR opiate (when appropriate) + one IR
• Goal is pain controlled to patient’s satisfaction 
Initial Opioid Dosing
• Morphine
• 2.5-5 mg PO q. 2-4 hours PRN
• 1 mg IV/SC q. hourly PRN
• Hydromorphone
• 1 mg PO q. 2-4 hours PRN
• 0.1-0.2 mg IV/SC q. 1 hour PRN
• Fentanyl
• 12-25 mcg IV/SC q. 1 hour PRN 
• Hydrocodone/Acetaminophen
• 2.5-5 mg PO of the hydrocodone component
• Hepatic CYP2D6hydromorphone 
Opiates in Renal or Hepatic Dysfunction 
Renal
• Codeine
• Do not use
• Fentanyl
• Generally safe
• May need dose reduction
• Hydromorphone
• 3-glucuronide metabolite can accumulate
• Methadone
• Safe
• Morphine
• Use with caution
• Active metabolites can accumulate
• Oxycodone
• Caution
• Parent drug and metabolites can 
accumulate
Hepatic
• Codeine
• Do not use
• Fentanyl
• Generally safe
• No dose adjustment necessary (1 dose)
• Hydromorphone
• Caution
• Reduce dose by 50%
• Methadone
• Do not use long-term 
• May accum in severe hepatic dysfunction
• Morphine
• Use with caution
• Conversion to inactive metabs may not 
happen; increase dosing intervals
• Oxycodone
• Use with caution
• Reduce initial dose 50% and monitor
Groninger H, Vijayan J Pharmacologic 
management of pain at end of life.  Am Fam
Physician 2014 Jul 1;90 (1):26-32
Methadone
• Racemic mixture of d- and l-isomers
• d-isomer is not an opiate but a potent N-methyl-D-aspartate 
antagonist
• Analgesia in neuropathic pain
• Long plasma half-life (can range from 12  to 150 hours)
• Steady state may take up to 4 weeks to achieve
• Doses should not be changed more frequently than weekly 
unless the patient is in a closely monitored setting
• Potential for QTc prolongation
• Watch drug interactions
• EKG in selected patients
• Caution in doses > 100 mg per day
• Should only be used by clinicians familiar with its 
unique properties
Brglio K, Abrahm J, Savarese D  Pain assessment and management in 
the last weeks of life.  UpToDate
Opiate Stewardship Education
• Sharing opioid medication with others may cause them to 
have serious reactions or death
• Selling or giving away opioid medication is illegal
• Store in safe AND secure place
• Children
• Family members
• Household visitors
• Wanted and unwanted
• Pets
• Proper disposal of unused medication
• Used fentanyl patch still has enough medication to harm or kill a 
child
Monograph: ER/LA Opioids: Achieving Safe Use While Improving 
Patient Care. August 2014 Collaborative for REMS Education, 
California Academy of Family Physicians
Behaviors Suggestive of Misuse
• Adverse life consequences (e.g., a lost job, relationship 
problems)
• Current abuse of other substances
• Indications of drug seeking behavior (e.g., seeks early 
refills)
• Lack of cooperation with opioid treatment plan (e.g., does 
not follow up with clinical team, refuses to use nonopioid 
therapies)
• Lack of reliability taking drug (e.g., self-titrates drug, runs 
out early)
• Loss of control of drug use (e.g., loses prescriptions)
Groninger H, Vijayan J Pharmacologic management of pain at end 
of life.  Am Fam Physician 2014 Jul 1;90 (1):26-32
Treatment Options for Neuropathic Pain
• First Line Pharmacologic Choices
• Tricyclic antidepressants
• Topical lidocaine
• Gabapentenoids
• Gabapentin
• Pregabalin
• Selective serotonin noradrenergic reuptake 
inhibitors (SNRIs)
• Venlafaxine
• Duloxetine
Haanpaa M, Gourlay G, et al. Treatment considerations for patients 
with neuropathic pain and other medical comorbidities. Mayo Clinic Proc March 
2010; 85(3)(suppl):S15-S25
Tricyclic Antidepressants
• Extensive literature re: efficacy
• Efficacy questionable in HIV and chemo Rx associated neuropathy
• Inexpensive
• Anti-cholinergic adverse effects may be limiting factor
• Secondary amine TCA better tolerated (nortriptyline; desimpramine)
• Start with 10 mg @ HS
• Increase by 10-25 mg every 3-7 days 75-100 mg
• Avoid or use with caution in elderly
• Avoid or use with great caution in pts with cardiac 
conduction disturbances or arrhythmia
• Contraindicated after recent MI
• Discuss with pharmacology consultant if any questions
SNRI’s
• Duloxetine
• Efficacy best shown in diabetic neuropathy
• Evidence for efficacy in chemotherapy induced neuropathy
• Adequate trial is 4 weeks
• Nausea is most common adverse effect
• Start 30 mg daily for 1 week, then increase to 60 mg daily
• No significant BP or cardiovascular effects
• Venlafaxine
• Two to for weeks needed to titrate to effective dose (150-225 mg/day)
• Adequate trial is 4-6 weeks
• Potential to increase BP
• Must taper if treatment discontinued
• Potential for very uncomfortable withdrawal syndrome
Dworkin R, O’Connor A, Audette J, et al. Recommendations for 
the pharmacological management of neuropathic pain: an 
overview and literature update. Mayo Clinic Proc March 2010; 
85(3)(suppl):S3-S14
Topical Lidocaine
• Efficacy of 5% lidocaine patch established in RCTs 
studying different types of NP pain
• Main use is for localized NP
• Helpful for allodynia
• Mild local reactions are main adverse reaction
• No significant systemic reactions or drug interactions
• Lidocaine 5% gel less expensive than patch and has 
demonstrated efficacy
Dworkin R, O’Connor A, Audette J, et al. Recommendations for the 
pharmacological management of neuropathic pain: an overview and 
literature update. Mayo Clinic Proc March 2010; 85(3)(suppl):S3-S14
Gabapentin
• Binds to voltage-gated calcium channels and inhibits 
neurotransmitter release
• Dose dependent dizziness and sedation
• Start at low doses (100 mg @ HS for elderly; otherwise 
100 mg TID) and titrate gradually
• Dosage reduction needed for renal insufficiency
• Dose Limits:
• Pain relief
• Intolerable side effects
• Maximum dose of 3600 mg daily in divided doses
• Angioedema an uncommon but reported adverse reaction
Pregabalin (Lyrica)
• Same mechanism of action as gabapentin
• Approved FDA 12/31/2004 
• Schedule V
• Starting dose is 50 mg TID
• Increase to 300 mg/day after 3-7 days
• Maximum dose is 600 mg/day, but no evidence of added efficacy 
above 300 mg/day
• Dose reduction needed for renal insufficiency
• Angioedema is a potential adverse reaction
• No clear evidence of superiority of pregabalin over 
gabapentin
Treatment Options for Neuropathic Pain
• A combination of gabapentin and an opioid has been 
shown to achieve better analgesia than either drug 
alone
• Gilron I, Bailey J, Tu D, et al. Morphine, gabapentin, or their combination for 
neuropathic pain. NEJM 2005;352(13):1324-1334
• Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the 
effects of existing gabapentin therapy in painful diabetic neuropathy patients. 
Eur J Pain 2008;12(6):804-813
• Combined gabapentin and nortriptyline therapy has 
been shown to be more efficacious than either drug 
given alone for post-herpetic neuralgia
• Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a 
double-blind, randomised controlled crossover trial. Lancet    
2009;374(9697):1252-1261
Other Potential Adjuvants 
• Glucocorticoids (dexamethasone)
• Topicals
• Lidocaine
• EMLA 
• Capsaicin
• Alpha-2 agonist
• Tizanidine
• Selective GABA-B agonist
• Baclofen
• Ketamine
Naloxone
• Criteria for Use: 
• Depressed mental status: difficult/unable to arouse 
• Shallow respirations or rate less than 8/minute + evidence of inadequate 
ventilation (e.g. low oxygen saturation, hypotension). 
• Stop opioid administration.
• Dilute 0.4 mg naloxone (one amp) with NS to total volume of 10 ml (0.04 mg/mL)
• Prompt pt to breathe deep breaths
• Administer 1 ml IV (0.04 mg) q1min until the patient is responsive. 
• A typical response is noted after 2-4 ml with deeper breathing and greater level 
of arousal. 
• If no response to 0.8 mg (2 amps), consider other causes of sedation and 
respiratory depression
• Repeated doses of naloxone, or even a continuous naloxone infusion, may be 
needed.
• Wait for sustained improvement in consciousness before restarting opioids at a 
lower dose
Dunwoody CJ, Arnold R. Using naloxone. Fast Facts and Concepts #039 End 
of Life/Palliative Education Resource Center
Opioid Dose Escalation
• For ongoing moderate to severe pain increase opioids 
doses by 50-100%, irrespective of starting dose
• For ongoing mild to moderate pain increase by 25-
50%, irrespective of starting dose
• Dosage escalations of less than 25% generally have 
no significant efficacy.
• Short-acting oral single-agent opioids can be safely 
dose escalated every 2 hours (clinician supervised)
• Sustained-release oral opioids can be escalated every 
24 hours.
Fast Facts #020 www.eperc.mcw.edu
Opiate Rotation
• Reduce opioid dose by 30-50% to accommodate for 
unknown cross-tolerance and titrate to goal.
• The wide variation among individuals is multifactorial and 
poorly understood.
• Incomplete cross-tolerance can lead to greater than 
anticipated potency in a new opioid, even though same 
class of analgesic is being used.
• Monitor clinical response and adverse effects.
Kishner S. Opioid equivalents Medscape
PCA
• Uses
• Pain is escalating and not controlled with oral regimen
• Persistent vomiting
• Transition after procedures
• More precise determination of opiate need
• Somnolence occurs before respiratory depression
• Basal infusion can be added once PRN use is assessed
• Typical starting dose in opiate naive pt:
• Hydromorphone 0.1 mg IV with 12 min lockout
• Morphine 1 mg IV with 12 min lockout
• Fentanyl 12 mcg with 12 min lockout
• Patient or nurse activated, NOT FAMILY!
PCA Conversion  
• 64 yo male, with metastatic SCC of lung with metastasis to liver, 
bone, and subcutaneous tissues has been on MS Contin 30 mg PO 
BID + 5 mg oral morphine every 2 hours PRN for breakthrough pain.  
In the last 24 hours he has used 5 doses of oral morphine, and 
presents to ED with vomiting and persistent pain that he rates 8/10.  
He has normal renal function and is alert.  You decide to rotate to 
hydromorphone using a PCA.
• Calculate total OME
• 30 + 30 + (5 x 5) = 85 mg in 24 hour = 3.5 mg per hour
• Convert to equivalent IV HYDROMORPHONE
• 3.5 ÷ 20 = 0.175 mg x 0.7 = 0.123 mg 0.1 mg IV hydromorphone per 
hour 
• PCA dose 0.1 mg hydromorphone with 12 min lockout
• Reassess pain control in 6-8 hours and adjust dose
Pain Crisis Management
• Morphine 2 mg IV initial dose
• If no response in 10 minutes repeat 2 mg dose
• If no response in 10 minutes, give 5 mg Q 10 min x 2 doses
• If no response give 10 mg Q 10 minutes until pain controlled
• Once a dose is starting to relieve pain, continue with that same 
bolus dose every 10 minutes until pain is 2-3/10.
• ONCE PAIN CONTROLLED:  calculate total amount of opiate used
• Give this amount over 24 hours as basal infusion with bolus dose the 
same mg as used for hourly infusion
• Example:
• 2 mg + 2 mg + 5 mg + 5 mg + 10 mg morphine  controls pain
• 24 mg ÷ 24 = 1 mg/hour basal morphine infusion
• PCA (or NCA) bolus 1 mg with 12 min lockout
• If pain starts to escalate, ↑ infusion + bolus by 100% & reassess
IV Lidocaine in Opioid-Resistant Pain
• Randomized, double-blinded, placebo-controlled, cross over 
study of 50 consecutive cancer patients not responding to 
maximally tolerated morphine dose
• Primary end-points:  Magnitude of pain relief and durability of 
response 
• Equal volumes of NS or Lidocaine
• Lidocaine
• 2 mg/kg bolus
• 2 mg/kg infusion over one hour
• ECG monitoring during bolus and for 2 hrs following infusion
• Non-invasive BP and respiratory rate monitoring every 10 min
Sharma S, Rajagopal M, Palat G, Singh C, et al.  A phase II pilot 
study to evaluate use of intravenous lidocaine for opoid-refractory 
pain in cancer patients. Journal of Pain and Symptom Management 
Jan 2009;(37)1:85-93
IV Lidocaine in Opioid-Resistant Pain
•Pain Types
•26 (52%) Mixed
•15 (30%) Nociceptive
• 9 (18%) Neuropathic
Sharma S, Rajagopal M, Palat G, Singh C, et al.  A phase II 
pilot study to evaluate use of intravenous lidocaine for opoid-
refractory pain in cancer patients. Journal of Pain and 
Symptom Management Jan 2009;(37)1:85-93
IV Lidocaine in Opioid-Resistant Pain
Lidocaine Placebo
Mean time to 40 min 75 min
maximal effect
Mean duration 9.34 days 3.82 days
of pain relief
% of patients reporting                      64% 30%
subjective decrease
in analgesic requirements
in 14 day f/u observation
period
Sharma S, Rajagopal M, Palat G, Singh C, et al  A phase II 
pilot study to evaluate use of intravenous lidocaine for opoid-
refractory pain in cancer patients. Journal of Pain and 
Symptom Management Jan 2009;(37)1:85-93
Summary 
• Pain has sensory and emotional elements
• Pain in EOL scenarios often has nociceptive and 
neuropathic aspects to consider
• Effective EOL pain management utilizes opiate and non-
opiate medication
• Escalating pain should be anticipated in EOL care
• Escalating pain can be effectively managed by family 
physicians
